Dr. David Donabedian is a Venture Partner at Longwood Fund and Chief Executive Officer and co-founder of Longwood portfolio company Axial Biotherapeutics. David is an accomplished business development and strategy executive with extensive leadership experience and a track record of building companies. Prior to joining Longwood, David held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GlaxoSmithKline (NYSE: GSK). At AbbVie he served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, David served as Vice President of Global New Deal Strategy & Development at GlaxoSmithKline and Senior Manager at Accenture's Strategic Services Consulting Group.
David holds a BA in Chemistry from St. Anselm College, a PhD in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.